# A Study Evaluating the Safety and Tolerability of Abrupt Discontinuation of Saredutant in Patients With Depression

> **NCT00429260** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 125 (actual)

## Conditions studied

- Depressive Disorder

## Interventions

- **DRUG:** Saredutant

## Key facts

- **NCT ID:** NCT00429260
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2007-06
- **Final completion:** 2007-06
- **Target enrollment:** 125 (ACTUAL)
- **Last updated:** 2012-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00429260

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00429260, "A Study Evaluating the Safety and Tolerability of Abrupt Discontinuation of Saredutant in Patients With Depression". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00429260. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*